Staff Fellow — Division of Bioinformatics and Biostatistics
Minjun Chen, Ph.D.
Dr. Minjun Chen received his Ph.D. degree from Zhejiang University, China in 2003. Starting in 2003, he worked as an assistant professor at the School of Pharmacy at Shanghai JiaoTong University in China, and was promoted to associate professor in 2005. In November 2006, Dr. Chen came to NCTR as a postdoctoral fellow jointly with the University of Medicine and Dentistry of New Jersey. He was promoted to an FDA staff fellow in the division in October 2008 and currently is a staff fellow in the division. During his research career, Dr. Chen has been the author or co-author of 78 peer-reviewed research articles, one book as the editor, six book chapters, and four technical reports. His work has been cited 3,277 times with an H-index of 31 based on the Google Scholar search as of June 7, 2018. He received the FDA award for “Outstanding Junior Investigator” in 2012, the NCTR “Scientific Achievement Award” in 2014, and the FDA "Scientific Achievement Award for Excellence in Analytical Science" in 2017. He established and currently co-chairs the FDA Liver Toxicity Working Group (LTWG) which is officially endorsed by the Office of the Chief Scientist with 60 FDA scientists involved to gather the expertise of drug-induced liver injury (DILI) within FDA. Dr. Chen is the editor of a book titled “Drug-Induced Liver Injury” with 92 contributing scientists from U.S. and EU, and published by Humana Press, Springer in 2018.
Dr. Chen's primary research interests encompass bioinformatics, drug safety, biomarker discovery, and toxicogenomics. His current research focus is in two areas:
Development of the Liver Toxicity Knowledge Base to address the concerns from public health and regulatory agencies related to liver toxicity caused by drugs and herbal dietary supplements.
Identification of biomarkers for predicting the outcome of chemotherapy of breast-cancer patients in support of precision medicine.
Professional Societies/National and International Groups
Mid-South Computational Biology & Bioinformatics Society
2008 – Present
Society of Toxicology (SOT)
2008 – Present
Council of Computational Toxicological Special Section, SOT
2018 – Present
Publication titles are linked to text abstracts on PubMed.
Elevated Bilirubin, Alkaline Phosphatase at Onset, and Drug Metabolism are Associated with Prolonged Recovery from DILI.
Ashby K., Zhuang W., González-Jimenez A., Alvarez-Alvarez I., Lucena M.I., Andrade R., Aithal G., Suzuki A., and Chen M.
J Hepatol. 2021.
The Landscape of Hepatobiliary Adverse Reactions Across 53 Herbal and Dietary Supplements Reveals Immune-Mediated Injury as a Common Cause of Hepatitis.
Zhu J., Chen M., Borlak J., and Tong W.
Arch Toxicol. 2020, 94 (1), 273-293.
Cancer Genomics Predicts Disease Relapse and Therapeutic Response to Neoadjuvant Chemotherapy of Hormone Sensitive Breast Cancers.
Zhu J., Muskhelishvili L., Tong W., Borlak J., and Chen M.
Sci Rep. 2020, 10 (1), 1-12.
The Development of a Database for Herbal and Dietary Supplement Induced Liver Toxicity.
Zhu J., Seo J.E., Wang S., Ashby K., Ballard R., Yu D., Ning B., Agarwal R., Borlak J., Tong W., and Chen M.
Int J Mol Sci. 2019, 19 (10), 2955.
Drug-Induced Liver Toxicity.
Chen M. and Will Y.
Humana Press. 2018.
Therapeutic Bile Acids and the Risks for Hepatotoxicity.
Ashby K., Navarro Almario E.E., Tong W., Borlak J., Mehta R., and Chen M.
Aliment Pharmacol Ther. 2018.
Direct-Acting Antivirals for Chronic Hepatitis C: Can Drug Properties Signal Potential for Liver Injury?
Mishra P. and Chen M.
Gastroenterology. 2017, 152 (6): 1270-1274.
A Model to Predict Severity of Drug-Induced Liver Injury in Humans.
Chen M., Borlak J., and Tong W.
Hepatology. 2016, 64(3):931-40.
DILIrank: The Largest Reference Drug List Ranked by the Risk for Developing Drug-Induced Liver Injury in Humans.
Chen M., Suzuki A., Thakkar S., Yu K., Hu C., and Tong W.
Drug Discov Today. 2016, 21(4):648-53. doi: 10.1016/j.drudis.2016.02.015. Epub 2016 Mar 3.
Drug-Induced Liver Injury: Interactions Between Drug Properties and Host Factors.
Chen M., Suzuki A., Borlak J., Andrade R.J., and Lucena M.I.
J Hepatol. 2015, 63(2):503-14.
A Testing Strategy to Predict Risk for Drug-Induced Liver Injury in Humans Using High-Content Screen Assays and the 'Rule-of-Two' Model.
Chen M., Tung C.W., Shi Q., Guo L., Shi L., Fang H., Borlak J., and Tong W.
Arch Toxicol. 2014, 88(7):1439-49.
Quantitative Structure-Activity Relationship Models for Predicting Drug-Induced Liver Injury Based on FDA-Approved Drug Labeling Annotation and Using a Large Collection of Drugs.
Chen M., Hong H., Fang H., Kelly R., Zhou G., Borlak J., and Tong W.
Toxicol Sci. 2013, 136(1):242-9.
High Lipophilicity and High Daily Dose of Oral Medications Are Associated with Significant Risk for Drug-Induced Liver Injury.
Chen M., Borlak J., and Tong W.
Hepatology. 2013, 58(1):388-96.
The Liver Toxicity Knowledge Base: A Systems Approach to a Complex End Point.
Chen M., Zhang J., Wang Y., Liu Z., Kelly R., Zhou G., Fang H., Borlak J., and Tong W.
Clin Pharmacol Ther. 2013, 93(5):409-12.
A Decade of Toxicogenomic Research and Its Contribution to Toxicological Science.
Chen M., Zhang M., Borlak J., and Tong W.
Toxicol Sci. 2012, 130(2):217-28.
FDA-Approved Drug Labeling for the Study of Drug-Induced Liver Injury.
Chen M., Vijay V., Shi Q., Liu Z., Fang H., and Tong W.
Drug Discov Today. 2011, 16(15-16):697-703.
Contact information for all lab members:
Jieqiang Zhu, Ph.D.
- Contact Information
- Minjun Chen
- (870) 543-7121
ExpertiseApproachDomainTechnology & DisciplineToxicology